New data from a rigorous randomised controlled trial reveal a striking finding: immunoadsorption therapy demonstrated zero percent significant benefit compared to sham treatment in 60 patients with post-COVID syndrome. This quantifiable result, published in The Lancet Regional Health – Europe, represents the first randomised evidence directly testing blood filtration approaches for long COVID management.
The German multicentre study employed a crossover design, allowing each participant to serve as their own control while receiving both active and sham procedures. This methodological rigor strengthens confidence in the negative findings. Immunoadsorption, a technique designed to remove potentially harmful autoantibodies and immune complexes, was based on the hypothesis that autoimmune mechanisms drive long COVID symptoms.
These results carry substantial weight for clinical practice, as they suggest blood filtration therapies may not represent effective treatment pathways for post-COVID syndrome despite theoretical immunological rationale. Read the full article on GMJ Newsroom.
Was this article helpful?
